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ABSTRACT 22 
Bacterial contamination of injectable stored biological fluids such as blood plasma and 23 
platelet concentrates preserved in plasma at room temperature is a major health-risk. Current 24 
pathogen-reduction technologies (PRT) rely on the use of chemicals and/or ultraviolet-light, 25 
which affects product quality and can be associated with adverse events in recipients. 405nm 26 
violet-blue light is antibacterial without the use of photosensitizers, and can be applied at 27 
levels safe for human exposure, making it of potential interest for decontamination of 28 
biological fluids such as plasma. 29 
As a pilot study to test whether 405nm light is capable of inactivating bacteria in biological 30 
fluids, rabbit and human plasma were seeded with bacteria and treated with a 405nm light 31 
emitting diode (LED) exposure system (patent pending).  Inactivation was achieved in all 32 
tested samples, ranging from low volumes to pre-bagged plasma. 99.9% reduction of low 33 
density bacterial populations 103 CFUml-1), VHOHFWHGWRUHSUHVHQWW\SLFDOµQDWXUDO¶34 
contamination levels, were achieved using doses of 144 Jcm-2. 35 
The penetrability of 405nm light, permitting decontamination of pre-bagged plasma, and the 36 
non-requirement for photosensitizing agents, provides a new proof-of-concept in bacterial 37 
reduction in biological fluids, especially injectable fluids relevant to transfusion medicine. 38 
(Word count: 190) 39 
 40 
KEY WORDS:  Plasma; Decontamination; 405nm light; violet-blue light; transfusion bags; 41 
pathogen reduction technology; Bacteria; Contamination 42 
 43 
3 
 
INTRODUCTION 44 
Bacterial contamination of ex vivo stored injectable biological fluids such as blood and blood 45 
components preserved in plasma is a major complication for transfusion medicine, resulting 46 
in both wasteful discarding of valuable blood products, and more significantly, health risks 47 
for recipients of contaminated donor blood [1,2].  Major progress has been made in the 48 
provision of a safe supply of blood components, and measures such as more effective donor 49 
screening, extensive laboratory testing protocols and the application of bacterial reduction 50 
methods have significantly reduced the risk of transfusion-transmitted bacterial infections [1-51 
3]. Nevertheless, the risk of bacterial transmission has not been completely eliminated and 52 
there is a recognised need for continued research to improve the efficacy of these methods, 53 
and to minimise incidental adverse changes in biological fluids, such as cellular blood 54 
components preserved in plasma, that can compromise product quality and safety [4-6]. 55 
A number of bacterial reduction methods have been developed for plasma treatment, and 56 
pathogen-reduced plasma is routinely used [7], with several of these methods now licensed 57 
for use in North America and Europe [5].  The original methods developed for plasma 58 
treatment included the use of solvent/detergent, and methylene blue in combination with 59 
visible light [8-11].  More recently developed methods have employed ultraviolet (UV) light.  60 
Exposure to amotosalen (S-59) plus long-wave ultraviolet (UVA) light [12,13], and treatment 61 
with riboflavin and UV light [7,14], have been developed to treat both plasma and platelets.  62 
Whilst light-based processes have typically used photosensitive chemicals to generate 63 
microbicidal effects, a UVC-based pathogen reduction system without a requirement for 64 
photoactive substances has been developed and is undergoing clinical efficacy and safety 65 
testing [15-17]. 66 
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It is generally accepted that all these methods have limitations [5,7], and because the full 67 
extent of future microbiological challenges cannot be predicted, pathogen reduction 68 
technologies will remain an active area of investigation in transfusion medicine well into the 69 
future [1,4].   70 
Here we report the first proof-of-concept results on the use of a novel visible violet-blue light 71 
method that does not require the addition of photosensitive chemicals for inactivation of 72 
bacterial pathogens in plasma.  This method utilises light with a peak wavelength of 405 nm, 73 
which causes photoexcitation of endogenous microbial porphyrin molecules and oxidative 74 
damage through reactive oxygen species [18]. 405 nm light has previously been shown to 75 
inactivate a wide range of bacterial pathogens in laboratory tests [19-28], as well as in 76 
hospital settings with use as an environmental disinfection technology [29-31], and also 77 
potential for wound decontamination applications in clinical settings [33-35].  An advantage 78 
of this technology over UV-light for certain applications is that, even at irradiance values and 79 
dose levels that are bactericidal, it can be applied safely for human exposure. Therefore, we 80 
envisioned that this feature makes 405 nm light of potential interest for decontamination of 81 
injectable stored biological fluids such as blood plasma or plasma containing cellular blood 82 
components.  Tests on bacterial-seeded plasma were carried out on both small-scale liquid 83 
samples and artificially-contaminated pre-bagged plasma.  Direct treatment of pre-bagged 84 
plasma was facilitated by the highly transmissible properties of 405 nm light, and the 85 
bacterial inactivation results obtained using this novel approach are described for the first 86 
time in this paper. 87 
 88 
 89 
 90 
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MATERIALS AND METHODS 91 
Bacterial Cultures:  The organisms used in this study were Staphylococcus aureus NCTC 92 
4135, Staphylococcus epidermidis NCTC 11964 and Escherichia coli NCTC 9001.  Cultures 93 
were obtained from the National Collection of Type Cultures (NCTC), Collindale, UK.  For 94 
experimental use, bacteria were cultured in 100 ml nutrient broth at 37°C under rotary 95 
conditions (120 rpm) for 18-h. Broths were centrifuged at 3939 u g for 10 minutes and the 96 
pellet re-suspended in 100 ml phosphate buffered saline (PBS), and serially diluted to obtain 97 
the required cell density (colony-forming units per millilitre, CFU ml-1) for experimental use.  98 
All culture media was sourced from Oxoid Ltd (UK). 99 
Plasma:  Lyophilised rabbit plasma (LRP020, E&O Laboratories, UK) was reconstituted 100 
using sterile distilled water.  Fresh frozen human plasma (approximately 300 ml bag volume) 101 
was obtained from the Scottish National Blood Transfusion Service (SNBTS, UK), and 102 
defrosted before experimental use.  Study involving human subjects protocol was approved 103 
by FDA Risk Involved in Human Subjects Committee (RIHSC, Exemption Approval # 11-104 
036B) and by the University of Strathclyde Ethics Committee (letter dated February 10, 105 
2011). Rabbit and human plasma suspensions were seeded with known concentrations of 106 
bacterial contaminants by adding bacterial-PBS suspension to the plasma. 107 
405-nm light source:  The 405 nm light sources used were rectangular arrays of 99-LEDs in 108 
an 11 × 9 matrix (Optodiode Corp, USA).  The array had a centre wavelength close to 109 
405 nm, with a bandwidth of approximately 10 nm at full-width half maximum (FWHM).  110 
The LED array was powered by a direct current supply, and for thermal management, the 111 
LED array was bonded to a heat sink and fan, thus ensuring that heating had no effect on the 112 
test samples exposed to the 405-nm light (Device patent pending [36]).   113 
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405 nm antimicrobial light treatment: Three arrangements were employed for 114 
exposure of three different sample volumes: 3 ml, 30 ml and approximately 300 ml (whole 115 
plasma transfusion bags).  For exposure of 3 ml sample volumes, the samples were held in 116 
the well of a 12-well microplate (without the lid), and the LED array was mounted in a 117 
polyvinyl chloride (PVC) housing which positioned the array approx. 3 cm directly above the 118 
sample.  Irradiance at the sample surface was measured to be approximately 100 mWcm-2 119 
(measured by using a radiant power meter and photodiode detector; L.O.T.-Oriel Ltd.).   120 
For exposure of 30 ml sample volumes, the human plasma was held in a sterile 90 mm Petri 121 
dish with the lid on.  The LED array was positioned 8 cm directly above the closed sample 122 
dish, providing an irradiance of approximately 8 mWcm-2, through the lid, at the centre of the 123 
sample dish.   124 
For exposure of plasma bags, a test rig was constructed which held two 405 nm LED arrays 125 
at a distance of 12 cm above the horizontally-positioned plasma bag.  This arrangement 126 
provided an irradiance of approximately 5 mWcm-2 at the centre position of the plasma bag, 127 
taking into account a 20% reduction in irradiance as the light transmits through the bag layer.  128 
In order to investigate the influence of higher irradiances on bacterial inactivation, plasma 129 
bags were also exposed using irradiances of 16 and 48 mWcm-2. These higher irradiances 130 
were achieved by using two high-power 405 nm LED arrays (PhotonStar Technologies, UK), 131 
with 14 nm FWHM.   132 
All experimental systems were held in a shaking incubator (72 rpm; 25°C) to allow 133 
continuous sample agitation and maintain exposure conditions.  Samples seeded with 134 
bacterial contamination were treated with increasing exposures of 405 nm light.  Control 135 
samples were held in identical conditions, but shielded from the 405 nm light.    136 
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The optical profiles of the light distribution across the Petri dishes and transfusion bags 137 
(plotted using MATLAB R2012b software) demonstrate the non-uniform irradiance of the 138 
plasma (Figs 2a, 3a), however, continuous agitation of the plasma samples during treatment 139 
ensure uniform mixing of the plasma contaminants. Negligible variation was recorded across 140 
the 22 mm ׎ of the 3 ml samples. 141 
Determination if Light Induces Toxicity within Human Plasma:  To ensure that bacterial 142 
inactivation was not the result of the plasma becoming toxic upon exposure to 405 nm light, 143 
S. aureus (1×103 CFUml-1) was seeded into 3 ml plasma that had been pre-exposed to 144 
1.08 kJcm-2 405 nm light at an irradiance of 100 mWcm-2 (the highest dose employed in the 145 
present study) and samples were taken at 30-min intervals for up to 3-hr. 146 
Bacterial Enumeration: Following 405 nm light exposure, samples were plated onto 147 
nutrient agar using either an automatic spiral plater (Don Whitley Scientific, UK) or manually 148 
spread by using sterile L-shaped spreaders, depending on the expected population density of 149 
the samples.  Sample plates were incubated at 37qC for 24 hours, and then enumerated with 150 
the surviving bacterial load reported as colony-forming units per mililitre (CFUml-1). 151 
Inactivation Data Analysis: Results are reported as surviving bacterial load (log10 CFU ml-152 
1) as a function of dose, and are presented as mean values from triplicate independent 153 
experiments (n=3).  Dose (J cm-2) is calculated as the product of the irradiance (W cm-2) 154 
multiplied by the exposure time (sec), with the irradiance value being the maximum 155 
measured at the centre position of the sample dish/bag.  Significant differences in the results 156 
were identified using 95% confidence intervals and one-way analysis of variance (ANOVA) 157 
with Minitab software Release 16.  For dose response curves the dose that reduces the log10 158 
CFU count at 0-dose by 50% was estimated.  This 50% log10 reduction was estimated using 159 
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curve fitting software (GraphPad Prism V6) and quadratic or 5PL variable slope sigmoidal 160 
curves with R-squared fits in excess of 90%. 161 
Optical Analysis of Plasma: The transmission values for rabbit and human plasma, PBS, 162 
and the blood bag material, were measured by using a Biomate 5 UV-Visible 163 
Spectrophotometer (Thermo Spectronic).  Analysis was carried out in the wavelength range 164 
220-700 nm.  Fluorescence spectrophotometry (RF-5301 PC spectrofluorophotometre; 165 
Shimadzu, US) was used to determine whether plasma or PBS contained photosensitive 166 
components which could be excited by 405 nm light.  Excitation was carried out at 405 nm 167 
and emission spectra were recorded between 500-700 nm. 168 
 169 
RESULTS 170 
Inactivation of Microbial Contaminants in 3 ml PBS and Plasma:  Results from the 171 
exposure of PBS, rabbit plasma and human plasma seeded with bacterial contamination 172 
(105 CFUml-1) to 100 mWcm-2 405nm light, are presented in Figure 1.  Results demonstrate 173 
that bacterial inactivation in PBS is achieved using the lowest dose.  Data for S. aureus 174 
(Fig.1a) shows that near complete inactivation (<10 CFUml-1 surviving) of the organism in 175 
PBS was achieved after exposure to a dose of 60 Jcm-2.  To achieve a comparable reduction 176 
in rabbit and human plasma, 4.5 times the dose was required (270 Jcm-2 compared to 60 Jcm-177 
2).  50% log10 reductions were estimated to occur at doses 23, 224 and 181 Jcm-2 for PBS, 178 
rabbit and human plasma, respectively. 179 
Similar inactivation kinetics were observed for S. epidermidis (Fig.1b), although this species 180 
showed comparatively greater susceptibility to 405 nm light when exposed in plasma.  The 181 
50% log10 reductions were obtained in PBS, rabbit and human plasma at 36, 121 and 174 182 
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Jcm-2 respectively.  Reduction of E. coli contamination required markedly increased doses 183 
(Fig.1c). The 50% log10 reductions required doses of 328, 585 and 742 Jcm-2 for PBS, rabbit 184 
and human serum respectively.  For inactivation in PBS, 450 Jcm-2 was required for near 185 
complete inactivation (<10 CFUml-1 surviving): 7.5 times more than observed with the 186 
staphylococci.  Inactivation of E. coli contamination in plasma again required increased doses 187 
compared to when suspended in PBS, with a 5-log10 reduction in human plasma achieved 188 
after a dose of 1.08 kJcm-2.   189 
 190 
Determination of Light Induced Toxicity within Human Plasma: No significant change in 191 
the seeded 103 CFUml-1 population [P=0.663] was evident in the bacterial contamination 192 
added to plasma post-exposure, thus indicating no residual toxicity in 405-nm light exposed 193 
plasma that could induce the inactivation of microbial contaminants. 194 
 195 
Inactivation of Contaminants in Larger Volumes of Human Plasma: 196 
30 ml Volume in Covered Sample Dish:  Figure 2 demonstrates the inactivation of 197 
low density S. aureus contamination in 30 ml plasma in a closed Petri dish using an 198 
irradiance of ~8 mWcm-2.  Results for a seeding density of 103 CFUml-1 (Fig 2b) demonstrate 199 
that exposure to doses of greater than 100.8 Jcm-2 caused significant inactivation of the 200 
contamination [P=0.030], with near-complete inactivation achieved with 230.4 Jcm-2.  201 
Control contamination levels rose significantly by approximately 1-log10 over the course of 202 
the experiment [P=<0.001].  Similar results were observed for inactivation of the 102 CFUml-203 
1
 contamination levels (Fig 2c): significant inactivation became evident after exposure to a 204 
dose of 115.2 Jcm-2 [P=0.009], with near complete inactivation achieved with 187.2±205 
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230.4 Jcm-2.  Control contamination levels remained relatively unchanged [P=0.255].  206 
Significant inactivation of a 101 CFUml-1 seeding population was shown after a dose of 207 
115.2 Jcm-2 [P=0.031], with near complete inactivation achieved by exposure to doses of 208 
201.6-230.4 Jcm-2 (Fig 2d).  Control contamination levels showed no significant change 209 
compared to the exposed samples [P=0.054]. 210 
Decontamination of Plasma in a Blood Bag:  Inactivation of low density (101-211 
102 CFU ml-1) bacterial contaminants within plasma transfusion bags was achieved using 212 
irradiances as low as 5 mWcm-2 (Fig.3b)   A notable downward trend in contamination was 213 
observed after exposure to 108 Jcm-2, with a significant 0.6 log10 reduction in contamination 214 
[P=<0.001].  Complete/near complete inactivation was achieved after exposure to 144 Jcm-2 215 
[P=0.017]  This slightly reduced inactivation rate, compared to that found within the sample 216 
dishes, is due to the lower irradiance light being used for exposure.  Contamination levels in 217 
the control plasma bags rose by approximately 0.5-log10 [P=0.052].  Similar inactivation 218 
kinetics were obtained for seeded transfusion bags exposed to irradiances of 16 and 219 
48 mWcm-2, with contamination levels decreasing upon exposure to increasing treatment.  220 
Comparison of the results for the three irradiance levels used, demonstrated that, when 221 
looking at exposure time (Fig. 4a), the decontamination effect observed with 16 and 222 
48 mWcm-2 is relatively comparable, with inactivation being slightly slower when using the 223 
lowest irradiance of 5 mWcm-2.  However, when looking at the actual dose levels applied 224 
(Figure 4b), it is apparent that the germicidal efficiency (defined as the log10 reduction of a 225 
bacterial population [log10(N/N0)] by inactivation per unit dose in Jcm-2 [23]) of the 5 mWcm-226 
2
 irradiance is greater than that of the 16 and 48 mWcm-2 irradiances (P=0.007 and 0.013, 227 
respectively).  Comparison of exposure to doses in the region of 140-180 Jcm-2 highlights this 228 
difference in efficacy, with a 1.91 log10 reduction being achieved after exposure to 5 mWcm-2 229 
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for 8h (144 Jcm-2), a 1.14 log10 reduction with 16 mWcm-2 for 3h (172.8 Jcm-2), but only 230 
0.08 log10 reduction observed after 1h exposure to 48 mWcm-2 (172.8 Jcm-2). 231 
Optical Analysis of Plasma:  Spectrophotometric analysis shows that transmission of 232 
405 nm light through plasma is low (1-2%) compared with transparent PBS (99%), and this 233 
correlates with the longer exposure times/increased doses required for comparative microbial 234 
inactivation in plasma compared to PBS.  Figure 5a highlights the transmissibility of the Petri 235 
dish material and the blood bag, with results showing that 405 nm light can transmit through 236 
these materials, thus permitting decontamination of the blood plasma whilst contained in the 237 
sample dish and blood bag.  The fluorescence emission spectra of rabbit and human plasma, 238 
and PBS demonstrated that excitation of the suspensions at 405 nm produced no prominent 239 
fluorescence emission peaks between 500 and 700 nm (Fig 5b). 240 
 241 
DISCUSSION 242 
In order to assess the potential of 405 nm light for decontamination of blood plasma, the 243 
penetrability and antimicrobial efficacy of 405 nm light in plasma required evaluation, and 244 
the aim of this study was to determine the antibacterial effects of 405 nm light at varying 245 
irradiances on bacteria seeded in blood plasma ranging from small volume samples up to pre-246 
bagged plasma. 247 
Initial investigation of the inactivation of bacterial contaminants in low volume (3 ml) plasma 248 
samples using 100 mWcm-2 405 nm light demonstrated that successful inactivation could be 249 
achieved in both rabbit and human plasma.  Significantly greater doses were required for 250 
inactivation of bacterial contaminants when suspended in plasma compared to PBS, and this 251 
is accredited to the differing optical properties of these suspending media.  The opacity, and 252 
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consequent low transmissibility of plasma (Fig.5a), reduces photon penetration through the 253 
suspension, resulting in the requirement for greater doses, compared with suspension in clear, 254 
transparent liquids such as PBS.  Despite this, these proof-of-principle results demonstrate 255 
that significant inactivation of bacterial contaminants in human plasma can be achieved, with 256 
the higher the irradiance of light applied, the shorter the exposure time required for successful 257 
inactivation. 258 
Despite the optical transmission properties of rabbit and human plasma being relatively 259 
similar, slight differences were recorded between the susceptibility of the bacterial 260 
contaminants when seeded in these media.  This is likely due to the batch-to-batch variation 261 
in color and opacity of the rabbit and, in particular, the human plasma.  Indeed, optical 262 
analysis of a number of human plasma bag samples (n=30) demonstrated variation in 263 
transmission at 405 nm of between 0.2-25% (Maclean, Anderson, MacGregor, Atreya; 264 
unpublished data).  This is likely the reason for the large standard deviation in some of the 265 
data points in the inactivation kinetics for the pre-bagged plasma. 266 
The bacterial species used in this study were selected to represent significant contaminants 267 
associated with blood components [3].  Although only three organisms were utilized, the 268 
wide antimicrobial efficacy of 405 nm light has been reported in a number of publications 269 
[20,22,23,25,37].  It is therefore expected that these organisms would also be successfully 270 
inactivated by 405 nm light when suspended in plasma.  Typically, Gram-positive bacteria 271 
tend to have greater susceptibility to 405 nm light than Gram-negative bacteria [23], and this 272 
is consistent with the results reported here, with approximately 4-times greater dose required 273 
to inactivate E. coli in plasma, compared to the staphylococci.  Interestingly, the difference 274 
between the susceptibilities of the staphylococci and E. coli was less pronounced when 275 
suspended in plasma compared to in PBS (4 versus 7.5 times the dose required). 276 
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The initial exposure tests in this study to establish proof-of-principle, utilised low volumes of 277 
plasma seeded with high population densities of bacterial contaminants at a level of 278 
105 CFUml-1.  A more realistic scenario involves larger volumes of plasma contaminated with 279 
low microbial densities.  Indeed, it has been reported that the levels of naturally-occurring 280 
bacterial contamination in plasma are likely to be as low as 10-100 bacterial cells per product 281 
at the beginning of storage [38].  Accordingly, experiments were scaled up 10 and 100-fold 282 
using larger plasma volumes seeded with bacterial contamination levels down to 101 CFUml-283 
1
, using S. aureus as the model organism.  Results demonstrated that bacterial contamination 284 
levels, even when less than 10 CFUml-1, can be significantly reduced in larger volumes of 285 
plasma by exposure to 405 nm light.  It was interesting to note that, when using similar 286 
irradiances, the bacterial inactivation rates in the 30 ml and 300 ml samples were very similar 287 
(~1.5 log10 reductions with a dose of 144 Jcm-2 ± Fig.2c, Fig.3b) despite the 10-fold 288 
difference in sample volume. Although the sample volumes were different, the depth of 289 
plasma was similar (~1-2 cm in both cases) thus indicating that, when using similar 290 
irradiances, it is the depth of plasma that is likely to influence the light inactivation efficacy, 291 
rather than the overall sample volume.  Also, results demonstrated that use of lower 292 
irradiances is likely to be more efficient, both in terms of optical energy and antimicrobial 293 
activity, than higher irradiances.  This is possibly due to there being a critical level of photons 294 
that can be involved in the photo-excitation of the bacterial porphyrin molecules, and above 295 
this irradiance level, there is provision of excess photons which, although exposing the cells, 296 
are unable to contribute to the reaction due to there being a limit on the free porphyrin to 297 
photon ratio.   298 
In addition to demonstrating efficacy when applied to larger volumes of plasma, these 299 
experiments highlighted that the 405 nm light disinfection effect can be achieved through 300 
transparent packaging.  A similar effect was reported in a recent study which highlighted the 301 
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ability of 405 nm light to decontaminate biofilms on the underside of transparent materials 302 
[39].  The ability of 405 nm light to transmit through the PVC bag layer to treat the plasma is 303 
particularly advantageous as it opens up the possibility for pre-bagged plasma to be treated 304 
immediately prior to storage, without the need for addition of photosensitizers, and/or passing 305 
the plasma through external decontamination systems, which can potentially introduce new 306 
contamination into the plasma products [6].  The transmissibility of 405 nm light is also a 307 
significant advantage over UVC-light, which is blocked by the PVC bag material (Fig.5a).  308 
Measurements in the present study demonstrated that transmission of 405 nm light though the 309 
blood component bag material resulted in an approximate 20% loss in irradiance, however 310 
light irradiance can be increased through the use of higher power light sources in order to 311 
compensate for this loss if required.  Future developments would also look to improve the 312 
uniformity of the light systems used to treat the plasma.   313 
Published studies have identified microbial endogenous porphyrin molecules as the key 314 
photosensitive targets which initiate the lethal oxidative damage exerted by 405 nm and other 315 
violet light wavelengths [19,33].  Since human blood also contains porphyrins and porphyrin 316 
derivatives, it was important to establish that inactivation by 405 nm light in our study was a 317 
result of the photoexcitation reaction within the microbial contaminants, and not a 318 
consequence of excitation of any photosensitive molecules within the plasma, and this was 319 
evidenced by the absence of antimicrobial toxicity to bacterial contaminants seeded into the 320 
405 nm light-exposed plasma.  Qualitative analysis of the rabbit and human plasma also 321 
detected no notable fluorescence emission peaks between 500-700 nm when excited at 322 
405 nm, thus indicating no significant levels of free porphyrins or other photoexcitation 323 
sources within the plasma that might have acted as exogenous photosensitizers for the 324 
inactivation of the microbial contaminants. 325 
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The 405 nm light doses required in this study for the decontamination of blood plasma have 326 
been in the region of 158 Jcm-2 and above.  These doses are relatively high compared to those 327 
typically required for other light-based methods, and this is due to the higher germicidal 328 
efficacy of UV-light compared to 405 nm light [40], and the involvement of photosensitizing 329 
compounds such as riboflavin, methylene blue and amotosalen, also accelerates the 330 
antimicrobial effects of light, with doses as low as 6.24 Jml-1 being reported as sufficient for 331 
use [7,41]; significantly lower than the 83 Jml-1 used in the present study (calculated based on 332 
the 158 Jcm-2 dose, transfusion bag dimensions and volume).  This benefit however is 333 
counterbalanced by the fact that photosensitizers are added to the blood products, and 334 
significant care must be taken to ensure there is no toxicity to the blood components or the 335 
recipient due to the presence of residual photosensitizers [6].  Methods utilizing UV-C light 336 
are currently under development and also demonstrate efficient microbial inactivation [16].  337 
Although not requiring photosensitizers, UV-C is naturally more germicidal than 405 nm 338 
light, however, as mentioned, the limited penetrability of shortwave UV-C radiation means it 339 
is unable to decontaminate plasma packed in blood bags, as evidenced in the present study 340 
using 405 nm light (Fig.4a).  The longer wavelength of 405 nm light also confers other 341 
benefits when compared to UV-light, including reduced polymer degradation and increased 342 
human safety [42,43]. 343 
Due to the absence of cells, solvent/detergent treatment, methylene blue and visible light, 344 
amotosalen and UV-A light, riboflavin and UV, and UV-C light are generally accepted as 345 
suitable for plasma decontamination. This study has generated significant evidence of the 346 
efficacy of 405 nm light for decontamination of blood plasma as a model system to study 347 
injectable biological fluids.  Since person-to person variation in the activity of plasma 348 
proteins in healthy individuals is known to be significant, any loss in plasma integrity due to 349 
405 nm light treatment is unlikely to have noticeable clinical impact. Further, since violet-350 
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blue light (405 nm) is relatively safer compared to already accepted UV-light based methods 351 
[40], its impact on plasma integrity has the potential to be reduced.  Nonetheless, it is 352 
important in future studies to establish what effects are imparted onto plasma proteins when 353 
exposed to antimicrobial levels of 405 nm light relative to UV light exposure. 354 
 355 
CONCLUSIONS 356 
Overall, this study provides the first evidence that 405 nm light has the ability to inactivate 357 
bacterial contamination within biological fluids such as blood plasma.  Significant 358 
inactivation of microbial contaminants was achieved in plasma samples of varying volumes 359 
held in different containers including pre-bagged plasma.  The penetrability of 405 nm light 360 
and the non-requirement for photosensitizing agents, provide this antimicrobial method with 361 
unique benefits that could support its further development as a potential alternative to UV 362 
light-based systems.  Further work is however required, not only to extend the 363 
microbiological data, but also to investigate the compatibility of 405 nm light with plasma 364 
components before its potential for plasma decontamination can be fully assessed.  Although 365 
this study has focused on the antimicrobial effects of 405 nm light for the decontamination of 366 
plasma, it will also be of interest to establish whether bacterial reductions can be achieved in 367 
platelets stored ex vivo in plasma-based suspensions, which have a significantly greater risk 368 
of contamination due to the limitations of their storage conditions. 369 
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528 
529 
 530 
Fig 1:  Inactivation of bacterial contamination, (a) S. aureus, (b) S. epidermidis (c) E. coli, in 531 
phosphate buffered saline (PBS) rabbit plasma, and human plasma, by exposure to 405 nm 532 
light with an irradiance of approximately 100 mWcm-2 (n=3 ±SD).  Non-exposed control 533 
samples for all experiments demonstrated no significant change in population over the 534 
exposure period [P=>0.05]. 535 
25 
 
536 
537 
 538 
Fig 2:  Inactivation of S. aureus contamination in 30 ml volumes of human plasma held in a 539 
closed sample dish by exposure to 405 nm light.  (a) Three-dimensional model demonstrating 540 
the irradiance profile across the sample dish, with an irradiance of ~8 mWcm-2 at the centre. 541 
Populations of (b) 103, (c) 102 and (d) 101 CFUml-1 were used as the seeding densities (n=3 542 
±SE).  Asterisks (*) represent data points where the bacterial levels in light-exposed plasma 543 
were significantly different to the equivalent non-exposed control [P=<0.05]. 544 
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 547 
Fig 3:  405 nm light exposure of contaminated human plasma transfusion bags (a) Three-548 
dimensional model demonstrating the irradiance profile across the plasma bag, with an 549 
irradiance of ~5 mWcm-2 at the centre (b) Inactivation of S. aureus contamination in 300 ml 550 
bags of human plasma by exposure to 405 nm light (n=3 ±SE).  Asterisks (*) represent data 551 
points where the bacterial levels in light-exposed plasma were significantly different to the 552 
equivalent non-exposed control [P=<0.05].  553 
 554 
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 555 
 556 
Fig 4: Comparison of the exposure times (a) and doses (b) required for inactivation of 557 
S. aureus contamination in human plasma transfusion bags. (a) Inactivation kinetics were 558 
achieved utilising irradiances of 5, 16 and 48 mWcm-2 at the centre of the bags.  Results are 559 
presented as log10 reduction (CFUml-1) as compared to the equivalent non-exposed control 560 
samples (n=3 ±SD). Germicidal efficiency (GE) values for each of the irradiances are shown 561 
on (b). (GE is defined as the log10 reduction of a bacterial population [log10(N/N0)]  by 562 
inactivation per unit dose in Jcm-2). 563 
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 564 
 565 
Fig 5: Optical analysis (a) Transmission properties of the Petri dish and blood bag material, 566 
highlighting 405 nm and UV-C light wavelengths for reference; (b) Fluorescence emission 567 
spectra of PBS and plasma (500-700 nm), detected using an excitation wavelength of 405 nm. 568 
 569 
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